Liver Dysfunction in COVID-19 Patients

Abnormal liver function is a frequent feature in patients with COVID-19, manifesting as mild to moderate elevations of serum transaminases, cholestasis or mixed biochemical patterns. Hepatic involvement ranges from transient dysfunction to acute decompensation in those with pre-existing chronic liver disease. Multiple mechanisms contribute to liver injury: direct viral entry into hepatocytes and cholangiocytes, systemic inflammation with cytokine release, hypoxia from respiratory failure, drug-induced toxicity and exacerbation of underlying metabolic or immune-mediated liver disorders. The degree of liver dysfunction correlates with overall disease severity and may serve as a prognostic indicator for intensive care requirement and mortality. Practical applications include routine monitoring of liver biochemistry, adjustment of potentially hepatotoxic therapies and targeted imaging for steatotic changes or biliary abnormalities. Globally, these findings underscore the need for integrated hepatology input in COVID-19 management pathways and reinforce the importance of vaccination and close follow-up in vulnerable subgroups such as cirrhotic or transplant patients.

Research from Nature Portfolio

A comprehensive review has delineated the hepatotropism of SARS-CoV-2, highlighting that liver cell types express key viral entry receptors and co-factors, enabling direct infection. Histopathological analyses reveal non-specific inflammation, microvascular thrombosis and steatosis in liver tissue. Abnormal liver biochemistry observed in hospitalised patients reflects a combination of direct cytopathic effects, systemic cytokine storm, hypoxic injury and drug-related harm. Importantly, patients with cirrhosis exhibit heightened rates of hepatic decompensation and death, likely driven by cirrhosis-associated immune dysfunction, whereas transplant recipients under immunosuppression may experience more tempered inflammatory responses. This work also addresses optimisation of SARS-CoV-2 vaccination in individuals with chronic liver disease and transplantation, and predicts that pandemic-related alterations in healthcare access and lifestyle may precipitate increased incidence and severity of liver disease in the coming years.

Liver Dysfunction in COVID-19 Patients publication trend

The graph below shows the total number of articles in liver dysfunction in covid-19 patients across all publications each year (not limited to Nature Index journals).

Technical terms

Cirrhosis: End-stage liver fibrosis characterised by architectural distortion and impaired function, often graded by clinical scoring systems.

Hepatic tropism: The affinity or capacity of a virus to infect and replicate within liver cells.

Transaminases: Enzymes (alanine aminotransferase and aspartate aminotransferase) released into the blood during hepatocellular injury.

Metabolic dysfunction-associated steatotic liver disease (MASLD): A spectrum of fatty liver conditions driven by metabolic risk factors, ranging from simple steatosis to steatohepatitis and fibrosis.

References

1. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients. Journal of Hepatology (2023).
2. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. Journal of Hepatology (2020).
3. Host determinants and responses underlying SARS-CoV-2 liver tropism. Current Opinion in Microbiology (2024).
4. COVID-19 and liver disease: mechanistic and clinical perspectives. Nature Reviews Gastroenterology & Hepatology (2021).
5. Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis. Tropical Medicine and Infectious Disease (2020).